Pliant Therapeutics Stock Market Value
| PLRX Stock | USD 1.11 0.02 1.77% |
| Symbol | Pliant |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pliant Therapeutics. Anticipated expansion of Pliant directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pliant Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Pliant Therapeutics requires distinguishing between market price and book value, where the latter reflects Pliant's accounting equity. The concept of intrinsic value - what Pliant Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Pliant Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Pliant Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pliant Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Pliant Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Pliant Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pliant Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pliant Therapeutics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Pliant Therapeutics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Pliant Therapeutics or generate 0.0% return on investment in Pliant Therapeutics over 90 days. Pliant Therapeutics is related to or competes with Zentalis Pharmaceuticals, Sutro Biopharma, Artiva Biotherapeutics, Clene, MacroGenics, Whitehawk Therapeutics, and Ovid Therapeutics. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel the... More
Pliant Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pliant Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pliant Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 22.72 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 4.59 |
Pliant Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pliant Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pliant Therapeutics' standard deviation. In reality, there are many statistical measures that can use Pliant Therapeutics historical prices to predict the future Pliant Therapeutics' volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.36) |
Pliant Therapeutics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.35) | |||
| Mean Deviation | 2.53 | |||
| Coefficient Of Variation | (689.00) | |||
| Standard Deviation | 3.51 | |||
| Variance | 12.29 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (0.36) | |||
| Maximum Drawdown | 22.72 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 4.59 | |||
| Skewness | (0.99) | |||
| Kurtosis | 3.72 |
Pliant Therapeutics Backtested Returns
Pliant Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.17, which implies the firm had a -0.17 % return per unit of risk over the last 3 months. Pliant Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pliant Therapeutics' Coefficient Of Variation of (689.00), risk adjusted performance of (0.11), and Variance of 12.29 to confirm the risk estimate we provide. The company holds a Beta of 1.43, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pliant Therapeutics will likely underperform. At this point, Pliant Therapeutics has a negative expected return of -0.59%. Please make sure to check Pliant Therapeutics' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Pliant Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.65 |
Good predictability
Pliant Therapeutics has good predictability. Overlapping area represents the amount of predictability between Pliant Therapeutics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pliant Therapeutics price movement. The serial correlation of 0.65 indicates that roughly 65.0% of current Pliant Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.65 | |
| Spearman Rank Test | 0.65 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.